Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity

The development of anti-drug antibodies (ADAs) following administration of biotherapeutics to patients is a vexing problem that is attracting increasing attention from pharmaceutical and biotechnology companies. This serious clinical problem is also spawning creative research into novel approaches t...

Descripción completa

Detalles Bibliográficos
Autor principal: Pratt, Kathleen P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698869/
https://www.ncbi.nlm.nih.gov/pubmed/31544871
http://dx.doi.org/10.3390/antib7020019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698869/
https://www.ncbi.nlm.nih.gov/pubmed/31544871
http://dx.doi.org/10.3390/antib7020019

Ejemplares similares